REG - Diaceutics PLC - Block Listing Application to AIM

DiaceuticsAnnouncement

02/10/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB4207Oa&default-theme=true

RNS Number : 4207O  Diaceutics PLC  02 October 2023

Block Listing Application to AIM

 

 

Belfast and London, 2 October 2023 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharmaceutical industry, today
announces an application has been made to AIM for a block listing of 1,500,000
ordinary shares of £0.002 each in the Company ("Ordinary Shares"). This will
be used to facilitate the admission of shares to trading following the
exercise of options granted under the following Company's share schemes:

 

 ·         the UK and Global Share Incentive Plan for employees (the "SIP"); and
 ·         the Employee Share Option Plan (the "ESOP") which includes long term incentive
           awards.

 

The Ordinary Shares will be issued from time to time pursuant to the Company's
existing plans including outstanding options already issued but not yet
exercised to the employees of the Company. New Ordinary Shares issued
following option exercises and admitted to trading under the block admission
will rank pari passu in all respects with the existing Ordinary Shares.

 

The block listing is expected to become effective on or around 6 October 2023.
The Company will make six-monthly announcements of the utilisation of the
block admission, in line with its obligation under AIM Rule 29.

 

At the time of this announcement, Diaceutics has 84,472,431 Ordinary Shares in
issue. This figure may be used by shareholders in the Company as a denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the share capital
of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information from Diaceutics PLC, please contact:

 

Enquiries:

 

 Diaceutics PLC                                         Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma                                                   Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBSBDGDUGDGXD